In order to test the effect of selenium on the anticancer activity of alkylating drugs, Seleno-TEPA (4), the selenium analog of the clinically used Thio-TEPA (1) was tested in vivo against the lymphocytic P 388 and lymphoid L1210 murine leukemias. Compound 4 is more active against P 388 leukemia than against L1210, and appears to be active over a narrower concentration range than Thio-TEPA (1). Compound 4 is less active against P 388 leukemia than 1, as evidenced by the T/C values of 164 for 4 and 239 for 1 at a dose of 4.2 mg/kg. The activity of 4 was also evaluated on the HL60 and K 562 human cell lines. Under the conditions of the cell colony assay technique, Seleno-TEPA (4) is less effective than Thio-TEPA (1).
Introduction
Recently, we compared [ 
Materials and Methods
Pure Thio-TEPA (1) was obtained from Lederle Laboratories (Pearl River. New York) and used without purification. The synthesis of Seleno-TEPA (4) was described previously [13] .
Preparation of hexamethylselenophosphoramide (5)
To a solution of hexamethylphosphorous triamide (1.63 g, 10 mmol) in benzene (25 ml) was added selenium (2.0 g, 25 mmol). The mixture was stirred at room temperature for 20 h, then filtered to remove the unreacted selenium. Concentration of the filtrate on a rotating evaporator at 20 °C/ 10-15 torr gave a white solid (2.45 g) which was purified by column chromatography on adsorption alumina, with dichloromethane as the eluant. The in vivo antitumor activity was evaluated against lymphocytic P 388 and lymphoid L1210 murine leukemias following the protocols of the National Cancer Institute [4] . Approximately 10 5 cells were injected i.p. into CDFI(CD2FI) mice at day 0 of the experiment (6 mice/group). Since 1, 4, and 5 are water soluble, the compounds were injected as saline solutions. Control animals consisted of mice which were inoculated with tumor cells but not treated with the test compounds and of healthy mice which were injected daily for 10 days with saline. At day 1, i.p. injections of test compounds began (0.005 ml/g weight) and continued for 10 days. The animals were then observed for 30 days keeping a record of deaths and survivors. Data were analyzed by the T/C method [4] where T represents the mean survival time of the treated group, and C the mean survival time of the tumor bearing control group. The percent of increase in life span (%ILS) parameter was evaluated by the formula [(T-C)/C] X 100. HL 60 cells were maintained in continuous liquid suspension culture [14] . The initial cell concentration was 2.5 X 10 5 cells/ml in RPMI (Roswell Park Memorial Institute) 1640 medium also containing 20% heat inactivated fetal calf serum (FCS), 0.3 mg/ml L-glutamine, 50 I.U./ml penicillin, and 5 jug/ml streptomycin. Unless stated otherwise, the HL 60 cell cultures were derived from cells cryopreserved after the 71st passage. Under these conditions, the cells had a population doubling time of approximately 48 h. The K 562 cells [15] were maintained in continuous liquid suspension culture. The initial cell concentration was 2.5 X 10 4 cells/ml in RPMI 1640 medium also containing 10% heat inactivated FCS, 0.3 mg/ml L-glutamine, 501.U./ml penicillin, and 50 jugjml streptomycin. Under these conditions, the cells had a population doubling time of approximately 24 h. HL60 and K 562 cells clone spontaneously in soft agar at 10-22% and 20-50% efficiency, respectively. The test compounds were evaluated against HL 60 and K 562 cells by incubating 5 x 10 3 cells/ml for 14 days in 35 mm Petri dishes at 37 °C, 100% humidity, and 7.5% C02 in the above medium, also containing 0.3% agar and the appropriate concentration of the test compound. After 14 days, colonies containing more than 50 cells were counted using a 20 X dissecting microscope.
Results and Discussion
The results of the in vivo studies of compounds 1, 4, and 5 with P388 and L 1210 inoculated mice are shown in Table I . Compound 4 appears to be more active against P388 leukemia than against L 1210 leukemia. Thus, against L 1210, the maximum T/C value, obtained at a dose of 5.7 mg/kg, is only 117, i.e., below the value of 125 which is required by the NCI protocol as the minimum T/C value for a drug to be considered as active, whereas against P388, the maximum T/C value is 164, obtained at the dose of 4.2 mg/kg. For the same system, in the case of Thio-TEPA (1), the maximum T/C value is much larger, i.e., 253, obtained at the concentration of 5.7 mg/kg. Although the doses for achieving maximum activity (T/C) for 1 and 4 are quite similar, i.e., only approximately 20% different, the magnitude of both the T/C and the % ILS is different for the two drugs. Thus, at a maximum T/C, the increase in life span for Thio-TEPA (1) treated animals is 153%, whereas for the Seleno-TEPA (4) treated mice, it is only 64%. Compound 4 appears to be active over a narrower concentration range as compared to Thio-TEPA. Thus, the therapeutic index for 4 is approximately 1.4, i.e., onehalf of the 2.75 value obtained for 1 [2] . Compound 5 appears to be inactive and nontoxic even at higher doses than those used in the case of 4.
Compound 4 was tested on two human cell lines, HL 60 and K 562. The HL 60 cell line is derived from peripheral blood leukocytes of a patient with acute progranulocytic leukemia [14] . The K 562 cell is derived from the pleural fluid of a patient with chronic myelogenous leukemia in blast crisis [15] . These cells w r ere incubated in the presence of Seleno-TEPA (4) and Thio-TEPA (1) in various concentrations. The results of the experiments are shown in Table II . Seleno-TEPA (4) appears to be more active against HL 60 than against K 562. Thus, against HL 60, 50% inhibition of colony formation is achieved at a concentration of approximately 6 X 10~7 M, while against K 562, similar inhibition is achieved at the higher dose of approximately 2 x 10~6 M. Thio-TEPA (1) is more effective against HL 60 than Seleno-TEPA, as evidenced by the result that 50% inhibition of colony growth is achieved at a dose of 2 x 10~7 M concentration of 1, and 6 X IO -7 M concentration of 4. It appears that compounds 1 and 4 interact analogously with the tumor cells, as can be seen from the plot of the log of the percent colonies as a function of drug concentration (Figure 1 ). In conclusion, unlike Thio-TEPA (1) which is equally effective [16] against P 388 and L 1210 leukemias in vivo the Seleno-TEPA (4) is active only against P 388. Although the replacement of the sulfur moiety in 1 with selenium affords a compound less active than the clinically used drug 1, the apparent reduced toxicity of Seleno-TEPA (4) as compared to 1 could be an important consideration in the designing of anticancer drugs. Fig. 1 . HL 60 cells incubated with Thio-TEPA (1) and Seleno-TEPA (4).
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